Article Figures & Data
Figures
- FIGURE 1.
Imaging and dosimetry. Day 0 posttracer (A) and day 2 posttherapy (B) SPECT/CT images of patient with CT-defined tumor outlines. Tumor-absorbed dose distribution with isodose contours in cGy (C) and tumor dose-volume histogram (D).
- FIGURE 2.
Baseline (A) and follow-up (B) PET/CT scans used to assess response after radioimmunotherapy (same patient as in Fig. 1).
- FIGURE 3.
Estimated relative HR for each decile-defined group based on mean tumor dose. HR here was calculated relative to HR for highest-dose decile group.
- FIGURE 4.
PFS (with number of subjects at risk and 95% confidence limits indicated) stratified by mean tumor-absorbed dose > 200 cGy and ≤ 200 cGy. Median PFS was 13.6 vs. 1.9 mo for the 2 dose groups (log-rank P < 0.0001).
Tables
Characteristic n or value Age (y) Median 54 Range 33–81 Male sex 29 (74) Histology Indolent* 31 (79) Transformed (diffuse large B cell) 8 (21) Stage of disease† I 4 (11) II 14 (37) III 11 (29) IV 9 (24) Chemotherapy‡ refractory 22 (56) No. of prior chemotherapy regimens Median 1 Range 1–5 Bone marrow involvement† 0% 26 (68) 1%–25% 12 (32) No. of tumor sites Median 3 Range 1–7 Presence of bulky disease§ 10 (26) High lactate dehydrogenase 12 (31) - TABLE 2
Univariate Analysis of Relationship Between Tumor Shrinkage at 2 Months and Covariates Evaluated at Tumor Level
Correlation with tumor volume shrinkage Parameter Median n P r* Baseline tumor volume (mL) 20 (1–716) 130 0.078 −0.166 Initial shrinkage (during tracer imaging) (%) 10 (–48 to 47) 130 0.163 0.132 Tracer-predicted mean tumor-absorbed dose (cGy) 248 (80–768) 130 0.002 0.290 Therapy-delivered mean tumor-absorbed dose (cGy) 275 (94–711) 124 0.021 0.222 Therapy-delivered minimum tumor dose (cGy) 130 (2–382) 124 0.078 0.171 Therapy-delivered tumor D99 (cGy) 156 (29–408) 124 0.034 0.204 Therapy-delivered tumor D80 (cGy) 216 (58–481) 124 0.021 0.222 Therapy-delivered equivalent biologic effect 0.87 (0.004−6.57) 124 <0.0001 0.490 ↵* Spearman rank correlation was used.
D99 and D80 = absorbed dose received or exceeded by 99% and 80%, respectively.
Data in parentheses are ranges.
- TABLE 3
Univariate Analysis of Relationship Between Patient Level Outcome Measures and Covariates
Outcome OR CR PFS Parameter Odds ratio* P Odds ratio* P HR* P Sex (M vs. F) 0.607 0.526 0.813 0.777 1.311 0.532 Age (y) 0.998 0.431 0.973 0.327 1.015 0.348 Stage (III/IV vs. I/II) 2.333 0.211 1.571 0.493 0.775 0.513 Histology (transformed vs. indolent) 0.550 0.455 0.640 0.584 1.492 0.362 Presence of bulky disease (Y vs. N) 0.163 0.024 0.400 0.242 1.604 0.291 Number of tumor sites 1.365 0.122 1.199 0.305 0.976 0.808 Marrow involvement (Y vs. N) 4.285 0.094 1.909 0.361 1.131 0.762 Elevated lactate dehydrogenase (Y vs. N) 0.824 0.784 1.250 0.748 1.488 0.313 Chemotherapy refractory (Y vs. N) 0.500 0.310 0.400 0.167 1.401 0.397 No. of prior chemotherapies 0.612 0.137 0.569 0.131 1.257 0.193 Tracer-predicted tumor-absorbed dose (cGy)† 1.468 0.061 1.535 0.032 0.773 0.020 Therapy-delivered tumor-absorbed dose (cGy)† 1.455 0.060 1.331 0.100 0.750 0.025 Therapy-delivered tumor equivalent biologic effect† 1.557 0.011 1.306 0.022 0.894 0.035
Jump to section
Related Articles
Cited By...
- The Costs to Our Patients
- Radioembolization Dosimetry with Total-Body 90Y PET
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy
- Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan